Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GYRE NASDAQ:MNMD NASDAQ:TIL NASDAQ:ZVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGYREGyre Therapeutics$7.64+3.5%$8.25$6.11▼$19.00$691.93M1.72143,249 shs56,153 shsMNMDMind Medicine (MindMed)$9.76+0.4%$7.63$4.70▼$10.44$734.38M2.451.23 million shs1.22 million shsTILInstil Bio$31.69-1.7%$27.25$9.85▼$92.00$211.46M2.15257,348 shs124,320 shsZVRAZevra Therapeutics$11.23-3.8%$9.83$5.45▼$13.16$638.11M1.971.39 million shs1.02 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGYREGyre Therapeutics-2.51%-0.14%-3.02%-18.63%-51.00%MNMDMind Medicine (MindMed)-1.92%+9.46%+36.13%+56.02%+11.47%TILInstil Bio+8.66%+16.39%+13.00%+152.27%+151.68%ZVRAZevra Therapeutics-0.85%-7.82%+27.54%+62.08%+87.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGYREGyre Therapeutics0.0192 of 5 stars0.01.00.00.00.00.80.0MNMDMind Medicine (MindMed)2.218 of 5 stars3.61.00.00.03.10.80.6TILInstil Bio2.458 of 5 stars3.52.00.00.00.63.30.6ZVRAZevra Therapeutics3.2568 of 5 stars3.65.00.00.03.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGYREGyre Therapeutics 3.00BuyN/AN/AMNMDMind Medicine (MindMed) 3.22Buy$24.00145.90% UpsideTILInstil Bio 3.00Buy$119.00275.51% UpsideZVRAZevra Therapeutics 3.11Buy$23.71111.17% UpsideCurrent Analyst Ratings BreakdownLatest TIL, GYRE, MNMD, and ZVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$25.00 ➝ $29.007/2/2025ZVRAZevra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/5/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$125.00 ➝ $125.006/2/2025TILInstil BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform ➝ Market Perform5/22/2025TILInstil BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$110.00 ➝ $105.005/14/2025ZVRAZevra TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/14/2025ZVRAZevra TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.00 ➝ $25.005/13/2025MNMDMind Medicine (MindMed)Cantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 7/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGYREGyre Therapeutics$105.76M6.77$0.20 per share37.37$1.05 per share7.28MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ATILInstil BioN/AN/AN/AN/A$25.96 per shareN/AZVRAZevra Therapeutics$23.61M26.01N/AN/A$0.74 per share15.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGYREGyre Therapeutics$12.09M$0.02382.19∞N/A7.20%9.73%7.66%8/12/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.29N/AN/AN/AN/A-40.33%-32.13%7/31/2025 (Estimated)TILInstil Bio-$74.14M-$11.97N/AN/AN/AN/A-45.52%-29.23%8/12/2025 (Estimated)ZVRAZevra Therapeutics-$105.51M-$1.90N/A56.15N/A-226.78%-201.05%-53.55%8/12/2025 (Estimated)Latest TIL, GYRE, MNMD, and ZVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025GYREGyre Therapeutics$0.03N/AN/AN/A$30.80 millionN/A8/12/2025N/ATILInstil Bio-$1.72N/AN/AN/AN/AN/A8/12/2025Q2 2025ZVRAZevra Therapeutics$0.65N/AN/AN/A$22.49 millionN/A7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.37N/AN/AN/AN/AN/A5/13/2025Q1 2025TILInstil Bio-$2.02-$4.32-$2.30-$4.32N/AN/A5/13/2025Q1 2025ZVRAZevra Therapeutics-$0.21-$0.06+$0.15-$0.06$16.96 million$20.40 million5/9/2025Q1 2025GYREGyre Therapeutics$0.03$0.03N/AN/A$28.40 million$22.06 million5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36-$0.35+$0.01-$0.35N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGYREGyre TherapeuticsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATILInstil BioN/AN/AN/AN/AN/AZVRAZevra TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGYREGyre TherapeuticsN/A3.603.19MNMDMind Medicine (MindMed)0.107.277.27TILInstil Bio0.5830.3330.33ZVRAZevra Therapeutics1.463.022.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGYREGyre Therapeutics23.99%MNMDMind Medicine (MindMed)27.91%TILInstil Bio60.56%ZVRAZevra Therapeutics35.03%Insider OwnershipCompanyInsider OwnershipGYREGyre Therapeutics10.00%MNMDMind Medicine (MindMed)2.45%TILInstil Bio47.20%ZVRAZevra Therapeutics2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGYREGyre Therapeutics4093.76 million84.38 millionNo DataMNMDMind Medicine (MindMed)4075.55 million73.70 millionOptionableTILInstil Bio4106.56 million3.46 millionNo DataZVRAZevra Therapeutics2054.68 million53.37 millionOptionableTIL, GYRE, MNMD, and ZVRA HeadlinesRecent News About These CompaniesReadystate Asset Management LP Purchases 616,370 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 23 at 6:13 AM | marketbeat.comAIGH Capital Management LLC Has $10.77 Million Stock Position in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)July 22 at 12:21 PM | marketbeat.comZevra Therapeutics (NASDAQ:ZVRA) Rating Lowered to "Buy" at Wall Street ZenJuly 22 at 2:13 AM | americanbankingnews.comZevra Therapeutics (NASDAQ:ZVRA) Downgraded to Buy Rating by Wall Street ZenJuly 20, 2025 | marketbeat.comZevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)July 18, 2025 | globenewswire.comQ2 EPS Forecast for Zevra Therapeutics Boosted by AnalystJuly 18, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Shares Acquired by Mystic Asset Management Inc.July 17, 2025 | marketbeat.comWilliam Blair Issues Optimistic Forecast for ZVRA EarningsJuly 17, 2025 | americanbankingnews.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics ...July 16, 2025 | finanznachrichten.deAre You Looking for a Top Momentum Pick? Why Zevra Therapeutics (ZVRA) is a Great ChoiceJuly 16, 2025 | zacks.com5 Small Drug Stocks to Buy Amid Trump's New Tariff ThreatsJuly 16, 2025 | zacks.comZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and MetabolismJuly 16, 2025 | globenewswire.comZevra Therapeutics Publishes Long-Term Efficacy and Safety Results for MIPLYFFA in Niemann-Pick Disease Type CJuly 16, 2025 | quiverquant.comQZevra Therapeutics (NASDAQ:ZVRA) Reaches New 12-Month High - Time to Buy?July 16, 2025 | marketbeat.comQ2 EPS Forecast for Zevra Therapeutics Raised by AnalystJuly 16, 2025 | marketbeat.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | finance.yahoo.comWall Street Analysts Predict an 86.55% Upside in Zevra Therapeutics (ZVRA): Here's What You Should KnowJuly 15, 2025 | zacks.comHere's Why 'Trend' Investors Would Love Betting on Zevra Therapeutics (ZVRA)July 15, 2025 | zacks.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Buy" by BrokeragesJuly 15, 2025 | americanbankingnews.comZevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Buy" from AnalystsJuly 15, 2025 | marketbeat.comCantor Fitzgerald Issues Positive Outlook for ZVRA EarningsJuly 14, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesForget the Weak Dollar—These 3 Travel Stocks Are Still Taking OffBy Chris Markoch | July 6, 2025View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off3 Stocks to Cushion Your Portfolio This Earnings SeasonBy Chris Markoch | July 16, 2025View 3 Stocks to Cushion Your Portfolio This Earnings SeasonTilray Shares Blazing: What's Behind the 55% Rally This Month?By Nathan Reiff | July 14, 2025View Tilray Shares Blazing: What's Behind the 55% Rally This Month?Palantir’s $100M Nuclear OS Pact Boosts Bullish CaseBy Chris Markoch | July 1, 2025View Palantir’s $100M Nuclear OS Pact Boosts Bullish Case3 Utility Stocks That Combine Income and StabilityBy Chris Markoch | July 2, 2025View 3 Utility Stocks That Combine Income and StabilityTIL, GYRE, MNMD, and ZVRA Company DescriptionsGyre Therapeutics NASDAQ:GYRE$7.64 +0.26 (+3.52%) Closing price 04:00 PM EasternExtended Trading$7.52 -0.11 (-1.51%) As of 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.Mind Medicine (MindMed) NASDAQ:MNMD$9.76 +0.04 (+0.41%) Closing price 04:00 PM EasternExtended Trading$9.68 -0.08 (-0.82%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Instil Bio NASDAQ:TIL$31.69 -0.55 (-1.71%) Closing price 04:00 PM EasternExtended Trading$31.05 -0.64 (-2.02%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Zevra Therapeutics NASDAQ:ZVRA$11.23 -0.44 (-3.77%) Closing price 04:00 PM EasternExtended Trading$11.16 -0.07 (-0.62%) As of 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Intel's Turnaround Gains Credibility With Strong Q2 Report Qualcomm's Next Gear: A Growth Story Wall Street Might Be Missing Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems CrowdStrike Scores Big With Gartner, But Valuation Is Stretched ServiceNow: The 2nd Wave of AI Spending Is Here Tractor Supply Revs Up on Forecast Hike and Bullish Signals A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
